Gender and the Parkinson's disease phenotype

Yasuhiko Baba, John D. Putzke, Nathaniel R. Whaley, Zbigniew K Wszolek, Ryan J. Uitti

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Objective: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67 %). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 %) was similar for both genders. A positive history of depression was significantly higher in females (35 % vs. 24 %). The UPDRS instability score was significantly worse among females, whereas the rigidity score was significantly worse for males. Females showed significantly worse ADL capacity and a more advanced H&Y stage. The proportion of individuals receiving antiparkinsonian medication (about 66 %) and time between the last dose and the clinical evaluation (about 4 hours) was similar for both genders. There was a trend for lower daily levodopa equivalence dosage and more severe dyskinesia score among females but these differences did not reach statistical significance after Bonferroni correction. Conclusions: The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristics. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.

Original languageEnglish (US)
Pages (from-to)1201-1205
Number of pages5
JournalJournal of Neurology
Volume252
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Parkinson Disease
Phenotype
Demography
Antiparkinson Agents
Dyskinesias
Levodopa
Activities of Daily Living
Age of Onset

Keywords

  • Clinical characteristic
  • Clinical cohort
  • Demographic
  • Gender
  • Historical
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Baba, Y., Putzke, J. D., Whaley, N. R., Wszolek, Z. K., & Uitti, R. J. (2005). Gender and the Parkinson's disease phenotype. Journal of Neurology, 252(10), 1201-1205. https://doi.org/10.1007/s00415-005-0835-7

Gender and the Parkinson's disease phenotype. / Baba, Yasuhiko; Putzke, John D.; Whaley, Nathaniel R.; Wszolek, Zbigniew K; Uitti, Ryan J.

In: Journal of Neurology, Vol. 252, No. 10, 10.2005, p. 1201-1205.

Research output: Contribution to journalArticle

Baba, Y, Putzke, JD, Whaley, NR, Wszolek, ZK & Uitti, RJ 2005, 'Gender and the Parkinson's disease phenotype', Journal of Neurology, vol. 252, no. 10, pp. 1201-1205. https://doi.org/10.1007/s00415-005-0835-7
Baba, Yasuhiko ; Putzke, John D. ; Whaley, Nathaniel R. ; Wszolek, Zbigniew K ; Uitti, Ryan J. / Gender and the Parkinson's disease phenotype. In: Journal of Neurology. 2005 ; Vol. 252, No. 10. pp. 1201-1205.
@article{cdc1c180f3474c9db103a87eb0af2c27,
title = "Gender and the Parkinson's disease phenotype",
abstract = "Objective: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67 {\%}). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 {\%}) was similar for both genders. A positive history of depression was significantly higher in females (35 {\%} vs. 24 {\%}). The UPDRS instability score was significantly worse among females, whereas the rigidity score was significantly worse for males. Females showed significantly worse ADL capacity and a more advanced H&Y stage. The proportion of individuals receiving antiparkinsonian medication (about 66 {\%}) and time between the last dose and the clinical evaluation (about 4 hours) was similar for both genders. There was a trend for lower daily levodopa equivalence dosage and more severe dyskinesia score among females but these differences did not reach statistical significance after Bonferroni correction. Conclusions: The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristics. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.",
keywords = "Clinical characteristic, Clinical cohort, Demographic, Gender, Historical, Parkinson's disease",
author = "Yasuhiko Baba and Putzke, {John D.} and Whaley, {Nathaniel R.} and Wszolek, {Zbigniew K} and Uitti, {Ryan J.}",
year = "2005",
month = "10",
doi = "10.1007/s00415-005-0835-7",
language = "English (US)",
volume = "252",
pages = "1201--1205",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "10",

}

TY - JOUR

T1 - Gender and the Parkinson's disease phenotype

AU - Baba, Yasuhiko

AU - Putzke, John D.

AU - Whaley, Nathaniel R.

AU - Wszolek, Zbigniew K

AU - Uitti, Ryan J.

PY - 2005/10

Y1 - 2005/10

N2 - Objective: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67 %). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 %) was similar for both genders. A positive history of depression was significantly higher in females (35 % vs. 24 %). The UPDRS instability score was significantly worse among females, whereas the rigidity score was significantly worse for males. Females showed significantly worse ADL capacity and a more advanced H&Y stage. The proportion of individuals receiving antiparkinsonian medication (about 66 %) and time between the last dose and the clinical evaluation (about 4 hours) was similar for both genders. There was a trend for lower daily levodopa equivalence dosage and more severe dyskinesia score among females but these differences did not reach statistical significance after Bonferroni correction. Conclusions: The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristics. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.

AB - Objective: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-based cohort. Methods: We examined gender differences in demographic, historical and clinical characteristics in a consecutive clinical series of 1264 individuals diagnosed with PD. Results: The majority of individuals in the sample were male (67 %). Comparative analyses showed males and females were not significantly different on most demographic and historical characteristics. For both genders, the mean age and the mean age at symptomatic onset were about 70 and 63 years, respectively and, thus, disease duration was not significantly different between genders. The proportion of individuals with a positive family history of PD (15 %) was similar for both genders. A positive history of depression was significantly higher in females (35 % vs. 24 %). The UPDRS instability score was significantly worse among females, whereas the rigidity score was significantly worse for males. Females showed significantly worse ADL capacity and a more advanced H&Y stage. The proportion of individuals receiving antiparkinsonian medication (about 66 %) and time between the last dose and the clinical evaluation (about 4 hours) was similar for both genders. There was a trend for lower daily levodopa equivalence dosage and more severe dyskinesia score among females but these differences did not reach statistical significance after Bonferroni correction. Conclusions: The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particularly in reference to historical and early disease stage characteristics. However, gender may be an important factor related to the expression of PD features during the symptomatic disease course.

KW - Clinical characteristic

KW - Clinical cohort

KW - Demographic

KW - Gender

KW - Historical

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=26644454585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26644454585&partnerID=8YFLogxK

U2 - 10.1007/s00415-005-0835-7

DO - 10.1007/s00415-005-0835-7

M3 - Article

C2 - 16151602

AN - SCOPUS:26644454585

VL - 252

SP - 1201

EP - 1205

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 10

ER -